Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-07-29FDA Approved: ZORYVE — Original Application (Arcutis Biotherapeutics, Inc.)
The FDA approved ZORYVE (roflumilast) under an original application for topical treatment of plaque psoriasis.
-
CLINICAL_TRIALS trial_result · 2022-07-29Clinical Trial Update: Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis [Phase 4]
Phase 4 trial update assessing efficacy, safety, preference, and response duration for Clobex Spray and Taclonex Ointment in plaque psoriasi…
-
FDA approval · 2022-07-18FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
The FDA approved Sandoz's supplemental application for the adalimumab biosimilar ADALIMUMAB-ADAZ. The approval covers multiple inflammatory …
-
CLINICAL_TRIALS trial_result · 2022-06-28Clinical Trial Update: CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis [Phase 3]
Phase 3 trial update for CF101 therapy in patients with moderate-to-severe plaque psoriasis has been completed.
-
FDA approval · 2022-06-17FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
The FDA approved a supplemental application for Enbrel (etanercept) from Immunex Corporation, resulting in labeling changes for the product.…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-06-16FDA Approved: SKYRIZI — Original Application (AbbVie Inc.)
FDA approved SKYRIZI (risankizumab-rzaa) from AbbVie in an original Biologics License Application. The approval covers adults with plaque ps…
-
FDA approval · 2022-06-14FDA Approved: SILIQ — Supplemental Application (Bausch Health US LLC)
FDA approved a supplemental application for SILIQ (brodalumab) submitted by Bausch Health US LLC.
-
FDA approval · 2022-05-31FDA Approved: FLUOCINOLONE ACETONIDE OIL — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for Fluocinonide Acetonide Oil from Rising Pharma Holdings, Inc., a topical corticosteroid produ…
-
CLINICAL_TRIALS trial_result · 2022-05-27Clinical Trial Update: Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy [Phase 4]
Phase 4 trial update evaluating the efficacy and safety of tildrakizumab in adults with moderate-to-severe chronic plaque psoriasis who did …
-
FDA approval · 2022-05-23FDA Approved: VTAMA — Original Application (Organon LLC)
The FDA approved VTAMA (tapinarof) from Organon LLC in its original application for the treatment of plaque psoriasis in adults.
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis [Phase 2]
Phase 2 study of Tapinarof Cream 1% in adults with extensive plaque psoriasis has completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-05-04Clinical Trial Update: Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]
Phase 3 trial update on pharmacokinetics, efficacy, safety, and immunogenicity of AVT02 for moderate to severe chronic plaque psoriasis.
-
CLINICAL_TRIALS trial_result · 2022-03-31Clinical Trial Update: A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis [Phase 2]
Phase 2 trial update on long-term safety, tolerability, and efficacy of bimekizumab in adults with chronic plaque psoriasis.
-
CLINICAL_TRIALS trial_result · 2022-03-04Clinical Trial Update: A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating the efficacy and safety of Bimekizumab in adults with moderate to severe chronic plaque psoriasis, using an initial…
-
CLINICAL_TRIALS trial_result · 2022-03-03Clinical Trial Update: A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis [Phase 3]
A Phase 3 trial evaluated efficacy and safety of two topical calcipotriol formulations in adults with mild to moderate plaque psoriasis; the…
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]
A Phase 3 study evaluating the efficacy and safety of bimekizumab in adults with moderate to severe chronic plaque psoriasis; results were p…
-
FDA approval · 2022-02-17FDA Approved: CLOBETASOL PROPIONATE — Original Application (Quagen Pharmaceuticals LLC)
FDA approved the original application for a generic clobetasol propionate topical product by Quagen Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2022-02-03Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]
Phase 3 study evaluating the efficacy and safety of bimekizumab versus placebo and an active comparator in adults with moderate-to-severe ch…
-
CLINICAL_TRIALS trial_result · 2022-01-20Clinical Trial Update: A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy [Phase 3]
Phase 3B open-label study assessing efficacy and safety of apremilast in plaque psoriasis not adequately controlled by topical therapy; comp…
-
CLINICAL_TRIALS trial_result · 2022-01-13Clinical Trial Update: A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life [Phase 4]
A Phase 4 trial evaluating apremilast (CC-10004) in adults with plaque psoriasis and impaired quality of life assessed quality of life, effi…
-
CLINICAL_TRIALS trial_result · 2021-12-28Clinical Trial Update: A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases [Phase 2]
Phase 2 trial evaluating KPL-716 for reducing pruritus in chronic pruritic diseases completed; results have been posted.
-
FDA approval · 2021-12-17FDA Approved: YUSIMRY — Original Application (Coherus BioSciences Inc)
FDA approved YUSIMRY (adalimumab-aqvh) from Coherus BioSciences in an original biologics license application, likely as a biosimilar to adal…
-
FDA approval · 2021-12-14FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc. The submission status …
-
CLINICAL_TRIALS trial_result · 2021-12-08Clinical Trial Update: Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis [Phase 4]
Phase 4 trial update on long-term treatment effect of tildrakizumab in participants with plaque psoriasis; study terminated.
-
CLINICAL_TRIALS trial_result · 2021-12-07Clinical Trial Update: Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05% [Phase 4]
Phase 4 clinical trial evaluating adrenal suppression potential and pharmacokinetics of halobetasol lotion 0.05% in plaque psoriasis was ter…